Slide Source www.lipidsonline.org Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Slides:

Advertisements

Similar presentations

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Advertisements

PPAR  activation Impact on pathways of clinical care.

Trial profile Fox K et al. Lancet 2008;372:

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.

FREEDOMS II TRIAL.

OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Randomized, double-blind, multicenter, controlled trial.

Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Azithromycin for the Secondary Prevention of Coronary Events J. Thomas Grayston, M.D., Richard A. Kronmal, Ph.D., Lisa A. Jackson, M.D., Alfred F. Parisi,

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Trial profile Mann JF et al. Lancet 2008;372:

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Effects of Ranolazine on Angina and Quality of Life Following PCI with Incomplete Revascularization -- The Ranolazine for Incomplete Vessel Revascularization.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

LEADER trial: Primary Outcome

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد

on behalf of the LEADER Trial Steering Committee and Investigators

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Effect of evolocumab on lipoprotein particles

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Trial profile John A Dormandy et al. Lancet 2005;366:

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Becker RC, et al. Lancet 2009;373:919-28

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Baseline Characteristics According to Sex

Study Participant Flow

Baseline Characteristics of the Study Participants

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

The ACCORD Study Group. NEJM 2010; Epub March 14

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

FIELD: Primary outcome

Increase of physical activity over time associated with lower HF risk

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators. Lancet 2005;366: Pioglitazone (514 events) Placebo (572 events) No. at Risk Time from Randomization (months) HR = 0.90 (95% CI ) p = 0.095

Slide Source Kaplan-Meier Curve of Time to Secondary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators. Lancet 2005;366: Pioglitazone (301 events) Placebo (358 events) No. at Risk Time from Randomization (months) HR = 0.84 (95% CI ) p = 0.027

Slide Source Baseline Change in Posterior-Wall Mean CIMT LS Mean Change from Baseline, mm No. of Observations Glimepiride Pioglitazone Week Glimepiride Pioglitazone Mazzone T et al. JAMA 2006;296:

Slide Source Baseline Change in Posterior-Wall Maximum CIMT LS Mean Change from Baseline, mm No. of Observations Glimepiride Pioglitazone Week Glimepiride Pioglitazone Mazzone T et al. JAMA 2006;296: